Anmeldung erfolgt in Kürze...
Details werden geladen...
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | The Manila Times
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Ähnliche Seiten
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | The Manila Times
https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/addex-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update/2372507
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
https://www.finanznachrichten.de/nachrichten-2026-06/68857865-addex-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update-399.htm
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/nrx-pharmaceuticals-nasdaqnrxp-reports-first-quarter-2026-financial-results-and-provides-corporate-update/2346083Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | The Manila Times
https://www.manilatimes.net/2026/06/11/tmt-newswire/globenewswire/vivoryon-therapeutics-nv-reports-q1-2026-financial-results-and-provides-business-update/2363280Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/rakovina-therapeutics-announces-q1-2026-financial-results-and-provides-corporate-update/2356285